Soluble complement receptor type 1 and antithrombin-III combination therapy prolongs xenograft survival: the role of thrombin and prostacyclin in hyperacute rejection.
Fujiwara
I
I
Second Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Nakajima
H
H
Akioka
K
K
Matsuda
T
T
Oka
T
T
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D015703:Antigens, CD; D000990:Antithrombin III / Q000032:analysis / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D006085:Graft Survival; D006168:Guinea Pigs; D016027:Heart Transplantation / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007700:Kinetics; D008297:Male; D015425:Myocardial Reperfusion; D010447:Peptide Hydrolases / Q000032:analysis; D051381:Rats; D011919:Rats, Inbred Strains; D017463:Receptors, Complement 3b; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000276:immunology / Q000502:physiology*; D014185:Transplantation, Isogeneic
D015703:Antigens, CD; D015415:Biomarkers; D017463:Receptors, Complement 3b; C046193:antithrombin III-protease complex; D015121:6-Ketoprostaglandin F1 alpha; D000990:Antithrombin III; D010447:Peptide Hydrolases